



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

WITZTUM, Joseph L., *et al.*

Serial No.: 10/705,448

Filed: November 11, 2003

For: METHODS FOR DIAGNOSING,
IMAGING AND TREATING
ATHEROSCLEROTIC DISEASE

Customer No.: 27111

Confirmation No.: 4879

Group Art Unit: 1641

Examiner: COOK, Lisa V.

Docket No.: XUCSD-1034916
[formerly 034123-013]

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON JUNE 29, 2006.

Jose R. Lopez, Jr.
Jose R. Lopez, Jr.

**THIRD INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Mail Stop **AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

07/10/2006 HDESTA1 00000148 501990 10705448
02 FC:1806 180.00 DA

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Forms PTO/SB/08b for consideration by the Examiner.

This Information Disclosure Statement is submitted:

☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.

☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

☐ A fee is required. A check in the amount of ____ is enclosed.

☒ A fee in the amount of \$180.00 is required. Please charge Deposit Account No. 50-1990 in the amount of \$180.00. A duplicate copy of this paper is included herewith.

☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.


☐ After mailing of a Final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1990** referencing **XUCSD-1034916** and please credit any excess fees to such deposit account. However, the Commissioner for Patents is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,


Dated: June 29, 2006

By: _____


Lin Yu
Registration No. 57,083

**Please recognize our Customer Number 27111
as our correspondence address.**

GORDON & REES, LLP
101 West Broadway, Suite 1600
San Diego, California 92101-8217
Phone: (619) 696-6700
Facsimile: (619) 696-7121
Attorney Docket No. XUCSD-1034916



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/705,448
Filing Date	November 11, 2003
First Named Inventor	WITZTUM, Joseph L., et al.
Art Unit	1641
Examiner Name	COOK, Lisa V.
Attorney Docket Number	XUCSD-1034916

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BARBAS, CF, et al., "Combinatorial Immunoglobulin Libraries on the Surface of Phage (pphabs): Rapid Selection of Antigen-Specific Fates," METHODS: A Companion to Methods in Enzymology, 1991, 2(2): 119-124, Academic Press, Inc., Burlington, MA	
		CHANG, M-K, et al., "Monoclonal Antibodies Against Oxidized LDL Bind to Apoptotic Cells and Inhibit Their Phagocytosis by Elicited Macrophages: Evidence That Oxidation Specific Epitopes Mediate Macrophage Recognition," Proc. Nat. Acad. Sci. U.S.A., 1999, 96:6353-	
		van der KOOIJ, MA, et al., "Human Monocyte-Derived Macrophages Express an Approximately 120-kD Ox-LDL Binding Protein With Strong Identity to CD 68", 1997, 17(11): 3107-3116.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.